RU2006101871A - Полиморфная форма а 4-{6-ацетил-3-{3-(4-ацетил-3-гидрокси-2- пропилфенилтио)пропокси}-2-пропилфенокси}масляной кислоты - Google Patents
Полиморфная форма а 4-{6-ацетил-3-{3-(4-ацетил-3-гидрокси-2- пропилфенилтио)пропокси}-2-пропилфенокси}масляной кислоты Download PDFInfo
- Publication number
- RU2006101871A RU2006101871A RU2006101871/04A RU2006101871A RU2006101871A RU 2006101871 A RU2006101871 A RU 2006101871A RU 2006101871/04 A RU2006101871/04 A RU 2006101871/04A RU 2006101871 A RU2006101871 A RU 2006101871A RU 2006101871 A RU2006101871 A RU 2006101871A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- composition according
- formula
- crystals
- polymorphic form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (16)
2. Композиция по п.1, в которой соединение формулы (1) находится в виде орторомбических кристаллов.
3. Композиция по п.1 или 2, которая дает, по существу, такой же профиль дифракции рентгеновских лучей в порошке (PXRD), как показано для полиморфной формы А на фиг.6.
4. Композиция по п.1, в которой, по меньшей мере, 90% соединения формулы (1) составляет полиморфная форма А при определении по высоте пика PXRD в районе 9° 2-тета.
5. Композиция по п.1, дополнительно включающая лактозу и микрокристаллическую целлюлозу.
7. Композиция по п.6, в которой изолированные кристаллы соединения (1) находятся в виде орторомбических кристаллов.
8. Композиция по п.6 или 7, в которой изолированные кристаллы соединения (1) проявляют, по существу, такой же профиль PXRD, как показано для полиморфной формы А на фиг.6.
9. Композиция по п.6, в которой изолированные кристаллы, по меньшей мере, на 90% представлены полиморфной формой А при определении по высоте пика PXRD в районе 9° 2-тета.
10. Композиция по п.6, в которой изолированные кристаллы соединения (1) содержат, по меньшей мере, 90% полиморфной формы А по отношению к другим полиморфным формам.
11. Таблетка, содержащая композицию по любому из пп.1-10.
12. Капсула, содержащая композицию по любому из пп.1-10.
13. Способ получения формы А соединения формулы (I)
включающий
(a) растворение соединения (1) в 5-10 вес.ч. теплого этанола и 1-10 частях воды;
(b) помешивание образовавшейся суспензии при 20-25°С в течение 15-60 мин;
(c) охлаждение до 5-10°С в течение дополнительного периода 1-4 ч;
(d) добавление 5-15 частей воды;
(e) помешивание смеси при 5-10°С в течение дополнительных 1-4 ч; и
(f) выделение кристаллов соединения (1).
14. Способ по п.14, в котором стадия (а) включает растворение соединения (1) в 5-10 вес.ч. этанола при 25-40°С и добавление в этанольный раствор 1-10 частей воды.
15. Способ по п.13 или 14, в котором стадия (с) проводится в течение 2,0-3,0 ч.
16. Способ по п.13, в котором стадия (с) проводится в течение 1,5-2,0 ч.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/601,862 | 2003-06-24 | ||
US10/601,862 US7064146B2 (en) | 2003-06-24 | 2003-06-24 | Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2006101871A true RU2006101871A (ru) | 2006-07-27 |
RU2317979C2 RU2317979C2 (ru) | 2008-02-27 |
Family
ID=33539463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006101871/04A RU2317979C2 (ru) | 2003-06-24 | 2004-06-24 | Изолированная орторомбическая кристаллическая форма 4-[6-ацетил-3-[3-(4-ацетил-3-гидрокси-2-пропилфенилтио)пропокси]-2-пропил-фенокси]масляной кислоты и фармацевтическая композиция на ее основе |
Country Status (11)
Country | Link |
---|---|
US (3) | US7064146B2 (ru) |
EP (1) | EP1636176A4 (ru) |
JP (2) | JP5518280B2 (ru) |
KR (1) | KR101120408B1 (ru) |
CN (1) | CN1812968B (ru) |
BR (1) | BRPI0411973A (ru) |
CA (1) | CA2530583C (ru) |
NO (1) | NO20060379L (ru) |
NZ (1) | NZ544319A (ru) |
RU (1) | RU2317979C2 (ru) |
WO (1) | WO2005000243A2 (ru) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7060854B2 (en) * | 2003-06-24 | 2006-06-13 | Medicinova, Inc. | Process for making polymorphic form A of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid |
US7064146B2 (en) * | 2003-06-24 | 2006-06-20 | Medicinova, Inc. | Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use |
RU2388466C2 (ru) | 2004-04-27 | 2010-05-10 | Медисинова, Инк. | Производные феноксиалкилкарбоновых кислот при лечении воспалительных заболеваний |
US8962687B2 (en) | 2012-12-05 | 2015-02-24 | Medicinova, Inc. | Method of treating liver disorders |
US8835499B2 (en) | 2011-12-08 | 2014-09-16 | Medicinova, Inc. | Method of treating non-alcoholic fatty liver disease and steatohepatitis |
US20150031769A1 (en) | 2013-07-25 | 2015-01-29 | Medicinova, Inc. | Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels |
US9346754B2 (en) | 2014-05-08 | 2016-05-24 | Medicinova, Inc. | Method of treating advanced non-alcoholic steatohepatitis |
US20150321989A1 (en) | 2014-05-08 | 2015-11-12 | Medicinova, Inc. | Method of treating idiopathic pulmonary fibrosis |
KR102435793B1 (ko) * | 2014-06-02 | 2022-08-25 | 메디시노바, 인크. | 섬유증의 억제 또는 치료 방법 |
WO2016033094A1 (en) | 2014-08-25 | 2016-03-03 | Aimmune Therapeutics, Inc. | Egg protein formulations and methods of manufacture thereof |
US20160220710A1 (en) * | 2015-01-30 | 2016-08-04 | The Regents Of The University Of Michigan | Compositions and methods for delivering pharmaceutical agents |
CA3217719A1 (en) | 2021-05-28 | 2022-12-01 | Kazuko Matsuda | Phenoxyalkylcarboxylic acid derivatives and their use in lowering triglyceride levels |
JP7478895B1 (ja) | 2022-11-30 | 2024-05-07 | 花王株式会社 | 痒みの予防又は改善剤 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5858146A (ja) * | 1981-10-05 | 1983-04-06 | Tanabe Seiyaku Co Ltd | 速放性マイクロカプセル |
US4710384A (en) * | 1986-07-28 | 1987-12-01 | Avner Rotman | Sustained release tablets made from microcapsules |
JPH07116125B2 (ja) * | 1988-03-07 | 1995-12-13 | 杏林製薬株式会社 | フェノキシアルキルカルボン酸誘導体及びその製造法 |
US4985585A (en) * | 1988-03-07 | 1991-01-15 | Kyorin Pharmaceutical Co., Ltd. | Phenoxyalkylcarboxylic acid derivatives and process for their preparations |
US5178878A (en) * | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
JPH06345682A (ja) * | 1993-06-11 | 1994-12-20 | Kyorin Pharmaceut Co Ltd | カルボン酸誘導体 |
JP3773064B2 (ja) * | 1994-09-13 | 2006-05-10 | 杏林製薬株式会社 | フェノキシアルキルカルボン酸誘導体の製造法 |
US5639475A (en) * | 1995-02-03 | 1997-06-17 | Eurand America, Incorporated | Effervescent microcapsules |
JPH1179985A (ja) | 1997-09-01 | 1999-03-23 | Kyorin Pharmaceut Co Ltd | 喘息治療用の粉末吸入剤 |
US7060854B2 (en) * | 2003-06-24 | 2006-06-13 | Medicinova, Inc. | Process for making polymorphic form A of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid |
US7064146B2 (en) * | 2003-06-24 | 2006-06-20 | Medicinova, Inc. | Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use |
-
2003
- 2003-06-24 US US10/601,862 patent/US7064146B2/en not_active Expired - Lifetime
-
2004
- 2004-06-24 EP EP04776980A patent/EP1636176A4/en not_active Withdrawn
- 2004-06-24 JP JP2006517585A patent/JP5518280B2/ja not_active Expired - Lifetime
- 2004-06-24 RU RU2006101871/04A patent/RU2317979C2/ru not_active IP Right Cessation
- 2004-06-24 WO PCT/US2004/020154 patent/WO2005000243A2/en active Application Filing
- 2004-06-24 KR KR1020057024889A patent/KR101120408B1/ko active IP Right Grant
- 2004-06-24 CA CA2530583A patent/CA2530583C/en not_active Expired - Fee Related
- 2004-06-24 NZ NZ544319A patent/NZ544319A/en not_active IP Right Cessation
- 2004-06-24 BR BRPI0411973-8A patent/BRPI0411973A/pt not_active IP Right Cessation
- 2004-06-24 CN CN200480017934.0A patent/CN1812968B/zh not_active Expired - Lifetime
-
2005
- 2005-12-29 US US11/319,272 patent/US7365224B2/en not_active Expired - Lifetime
-
2006
- 2006-01-24 NO NO20060379A patent/NO20060379L/no not_active Application Discontinuation
-
2008
- 2008-04-21 US US12/106,939 patent/US7728169B2/en not_active Expired - Lifetime
-
2013
- 2013-12-24 JP JP2013265114A patent/JP2014097989A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
NO20060379L (no) | 2006-03-24 |
CA2530583A1 (en) | 2005-01-06 |
KR20060030484A (ko) | 2006-04-10 |
US7064146B2 (en) | 2006-06-20 |
JP2007524624A (ja) | 2007-08-30 |
EP1636176A4 (en) | 2010-03-31 |
NZ544319A (en) | 2008-12-24 |
CN1812968A (zh) | 2006-08-02 |
CN1812968B (zh) | 2016-07-27 |
US7728169B2 (en) | 2010-06-01 |
WO2005000243A2 (en) | 2005-01-06 |
BRPI0411973A (pt) | 2006-08-29 |
EP1636176A2 (en) | 2006-03-22 |
US7365224B2 (en) | 2008-04-29 |
JP2014097989A (ja) | 2014-05-29 |
KR101120408B1 (ko) | 2012-03-15 |
US20080292698A1 (en) | 2008-11-27 |
RU2317979C2 (ru) | 2008-02-27 |
US20060135604A1 (en) | 2006-06-22 |
CA2530583C (en) | 2010-08-10 |
WO2005000243A3 (en) | 2005-04-28 |
US20040266878A1 (en) | 2004-12-30 |
JP5518280B2 (ja) | 2014-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU593295B2 (en) | Paroxetine hydrochloride hemihydrate | |
RU2006101871A (ru) | Полиморфная форма а 4-{6-ацетил-3-{3-(4-ацетил-3-гидрокси-2- пропилфенилтио)пропокси}-2-пропилфенокси}масляной кислоты | |
JP5422545B2 (ja) | リン酸カルベジロール塩および/またはその溶媒和物、対応する組成物、および/または治療方法 | |
CA2958625C (en) | Crystal of pyrrole derivative and method for producing the same | |
EA001534B1 (ru) | Производные циклической аминокислоты или их фармацевтически приемлемые соли, фармацевтическая композиция и способ лечения депрессии, состояний паники, страха и болевых ощущений | |
RU2003130268A (ru) | Производные 4,5-дигидро-1h-пиразола, обладающие сильной cb1-антагонистической активностью | |
CH668426A5 (de) | Thiazole, ihre herstellung und verwendung. | |
HUE023239T4 (en) | Modulators of the prostacycline (PGI2) receptor that can be used to treat related diseases | |
EP1476443A2 (en) | Process for preparing indolinone derivatives | |
TW318830B (ru) | ||
JP6507267B2 (ja) | 選択的ヒストンデアセチラーゼ阻害剤としてのヘテロ環状アルキル誘導体化合物及びこれを含有する薬剤学的組成物 | |
RU2006142768A (ru) | Способ получения бисульфата атазанавира | |
SU728713A3 (ru) | Способ получени производных салициланилида | |
CN1008062B (zh) | 制备改进的抗炎药炎痛喜康盐类的方法 | |
US10442770B2 (en) | Solid state forms of netarsudil mesylate | |
JP2006503024A (ja) | Vi型アトルバスタチンカルシウムまたはその水和物 | |
BRPI0712372A2 (pt) | cloridrato cristalino de duloxetina | |
US8785663B2 (en) | Polymorphic forms of Lubiprostone | |
RU2355685C2 (ru) | Амидометилзамещенные производные 2-(4-сульфониламино)-3-гидрокси-3, 4-дигидро-2н-хромен-6-ила, способ и промежуточные продукты для их получения и содержащие эти соединения лекарственные средства | |
BRPI0415109A (pt) | compostos de 1-[2-(4-hidroxifenil)-2-hidroxietil]-piperidin-4-ol como antagonistas de receptor de nmda | |
JPH05306277A (ja) | 抗腫瘍剤および腫瘍の治療方法 | |
JPH0153266B2 (ru) | ||
US4156002A (en) | Pharmaceutical compositions | |
CN1064809A (zh) | 药剂 | |
JP3213324B2 (ja) | 新規なn−ベンゾイルメチル−ピペリジン類 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20120625 |